Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of mesalamine delayed-release tablets versus Asacol in mild to moderately active ulcerative colitis
2007-004732-23Phase 3Completed
- Sponsor
- EMET Pharmaceuticals
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Salcrozine in autoimmune colitis (3 arms), sponsored by EMET Pharmaceuticals. Primary endpoint: Treatment success or treatment failure. Started Oct 2007; status: completed.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2007-004732-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004732-23.